CANnabidiol for Parkinson’s Disease Psychosis | C4C

To obtain preliminary evidence regarding safety, tolerability, maximum tolerated dose, potential drug-drug interactions and whether there is a proof-of-concept evidence of drug activity that can inform a future pivotal efficacy study with cannabidiol (CBD) in Parkinson’s disease psychosis (PDP). Furthermore, we want to obtain mechanistic evidence that supports a clinical development rationale by examining whether short-term treatment with CBD engages with the neural substrates that may function abnormally to cause psychotic symptoms in PDP, and whether CBD has an effect consistent with amelioration of these brain function abnormalities.